

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/739,933
				Filing Date	December 18, 2000; Conf. No. 4882
				First Named Inventor	James Steven Reid
				Art Unit	1649
				Examiner Name	STACEY NEE MACFARLANE
Sheet	1	of	12	Attorney Docket Number	108091-0002-103

U. S. PATENT DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US- 4,863,902	09-05-1989	Amagase et al.	
		US- 5,851,832	12-22-1998	Weiss et al.	
		US- 5,942,487	08-24-1999	Ogawa et al.	
		US- 6,486,122	11-26-2002	Twardzik et al.	
		US- 6,677,307	01-13-2004	Twardzik et al.	
		US- 6,764,683	07-20-2004	Twardzik et al.	
		US- 6,815,418	11-09-2004	Twardzik et al.	
		US- 7,329,645	02-12-2008	Twardzik et al.	
		US- 7,365,172	04-29-2008	Twardzik et al.	
		US- 20020193301	12-19-2002	Twardzik et al.	
		US- 20080242611	10-02-2008	Twardzik et al.	
		US- 20090068139	03-12-2009	Twardzik et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> "Number" <sup>4</sup> "Kind Code" <sup>5</sup> (if known)				
		WO 00/65028	11-02-2000	Stem Cell Pharmaceuticals, Inc.		
		WO 01/12127	02-22-2001	Stem Cell Pharmaceuticals, Inc.		

Examiner Signature	Date Considered
-----------------------	--------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/739,933
				Filing Date	December 18, 2000; Conf. No. 4882
				First Named Inventor	James Steven Reid
				Art Unit	1649
				Examiner Name	STACEY NEE MACFARLANE
Sheet	2	of	12	Attorney Docket Number	108091-0002-103

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ABBOUD, et al., "Insulin Effects on Differentiation of Fetal Neuron Cell Cultures," Soc . Neurosci. Abstr. 23 : 1425, 1997	
		"Adult stem cells activated in mammalian brain", http://today.uci.edu/news/release_detail.asp?key=1801, 7/24/08	
		ALHEID, et al., "Theories of basal forebrain organization and the "emotional motor system", " Progr. Brain Res. 107:461-484, 1996	
		ANDERSSON, et al., "Differential Expression Of Fgfri - R4 In The Rat Nervous System", Dept. Cell Biology & Anatomy, Oregon Health Services University, Portland, OR 97201, Society for Neuroscience Abstracts Volume 20, 1994, p. 40	
		BABIC, et al., "CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth," Proc. Natl Acad. Sci. USA, 95:6355, 1998	
		BARNARD, et al., "Auto- and Cross-induction within the Mammalian Epidermal Growth Factor-related Peptide Family*, "J. Biol. Chem. 269 : 22817 - 22822, 1994	
		BAYER S., "Neurogenesis in the Rat Neostriatum," Intl. J. Devel. Neurosci. 2 : 163 - 175, 1984	
		BAYER, et al., "Directions in Neurogenetic Gradients and Patterns of Anatomical Connections in the Telencephalon," Prog. Neurobiol. 29 : 57 - 106, 1987	
		BLOMQUIST, et al., "Vaccinia virus 19-kilodalton protein: Relationship to several mammalian proteins, including two growth factors," Proc. Natl. Acad. Sci. USA 81 : 7363 - 7367, 1984	
		BOONSTRA, et al., 1995 Cell Biology Int'l 19(5):413-430	
		BORGUNDAAG, et al., "Dopamine receptor activation inhibits estrogen-stimulated transforming growth factor-alpha gene expression and growth in anterior pituitary, but not in uterus," Endocrinol. 130 : 3453 - 3458, 1992	
		BRAZELTON, T., "From Marrow to Brain: Expression of Neuronal Phenotypes in Adult Mice," (2000) Science 290:1775	
		BURGESS, et al., "Possible Dissociation of Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue", J of Cell Bio. 1990, 111:2129-2138	
		CASPER, et al., "EGF Enhances the Survival of Dopamine Neurons in Rat Embryonic Mesencephalon Primary Cell Culture," J. Neurosci. Res. 30:372-381, 1991	
		CASPER, et al., "Epidermal Growth Factor and Basic Fibroblast Growth Factor Protect Dopaminergic Neurons from Glutamate Toxicity in Culture," J. Neurochem. 65:1016-1026, 1995	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/739,933
				Filing Date	December 18, 2000; Conf. No. 4882
				First Named Inventor	James Steven Reid
				Art Unit	1649
				Examiner Name	STACEY NEE MACFARLANE
Sheet	3	of	12	Attorney Docket Number	108091-0002-103

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		CATAPANO, et al., "Human Fetal Precursor Cells are Capable of Survival, Neuronal Differentiation, and Integration Following Transplantation into Neonatal Rat Brain," Soc. Neurosci. Abstr. 23 : 345, 1997	
		Centers for Disease Control and Prevention, <a href="http://www.cdc.gov">www.cdc.gov</a>	
		CHALAZONITIS A. et al., Transforming Growth Factor , But Not Epidermal Growth Factor, Promotes The Survival Of Sensory Neurons In Vitro" <i>In Vitro</i> 1992 Journal of Neuroscience 12(2):583-594	
		CLARKE, et al., "Reactive astrocytes express the embryonic intermediate neurofilament nestin," Neuroreport, 5 : 1885 - 1888, 1994	
		CODE, et al., "Some transforming growth factor-alpha connections and their colocalization with enkephalin in the rat central nervous system," Brain Res. 421:401-405, 1987	
		COFFEY, et al., "Production and auto-induction of transforming growth factor-α in human keratinocytes," Nature 328 : 817 - 820, 1987	
		CONNOR B., et al., "The Role Of Neuronal Growth Factors In Neurodegenerative Disorders Of The Hyman Brain," 1998 Brain Research Reviews 27: 1-39	
		COOPER, et al, "Intrastriatal transforming growth factor α delivery to a model of parkinson's disease induces proliferation and migration of endogenous adult neural progenitor cells without differentiation into dopaminergic neurons", J. Neurosci. 2004 October 13; 24(41):8924-8931	
		DERYNCK, "Transforming Growth Factor-α" (1990) Molecular Reproduction and Development 27:3-9*	
		DHURIA SV - J Pharm Sci 99:1654-1673 – Intranasal delivery to the central nervous system: mechanisms and experimental considerations. – (2010)	
		EARP, et al., "Epidermal Growth Factor (EGF) Stimulates EGF Receptor Synthesis*", J. Biol. Chem. 261 : 4777 - 4780, 1986	
		ERIKSSON, et al., "Neurogenesis in the adult human hippocampus," NatMed 4:1313-1317 – (1998)	
		EZEONU, et al., "Cell fate decisions in a human retinal precursor cell line: basic fibroblast growth factor- and <b>transforming growth factor-alpha</b> -mediated differentiation", DNA Cell Bio.2000 Sep; 19(9):527-37	
		EZEONU, et al., "Density-dependent differentiation in nontransformed human retinal progenitor cells in response to basic fibroblast growth factor-and <b>transforming growth factor-alpha</b> ", DNA Cell Biol, 2003 Oct; 22(10): 607-20	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/739,933
				Filing Date	December 18, 2000; Conf. No. 4882
				First Named Inventor	James Steven Reid
				Art Unit	1649
				Examiner Name	STACEY NEE MACFARLANE
Sheet	4	of	12	Attorney Docket Number	108091-0002-103

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		FALLON, et al., "Epidermal Growth Factor Receptor mRNA Is Increased In The Striatum Of Rats With 6ohba Lesions Of The Substantia Kigra And Intrastriatal Transplants In The Caudate Putamen" Department of Anatomy and Neurobiology, University of California, Irvine, Irvine, CA 92717, Society for Neuroscience Abstracts Volume 20, 1994, p. 40	
		FALLON, et al., "The Rat Nervous System", G. Paxinos, Ed., pp. 215-237, Academic Press, San Diego, 1995	
		FALLON, et al., Cerebral Cortex, E.G. Jones and A. Peters, Eds., Vol. 6, pp. 41-127, Plenum Press, New York, 1987	
		FALLON, et al., "Epidermal Growth Factor Immunoreactive Material in the Central Nervous System: Location and Development," Science 224:1107-1109	
		FALLON - Growth Factors 6:139-157 - Localization of Acidic Fibroblast Growth Factor Within the Mouse Brain Using Biochemical and Immunocytochemical Techniques - (1992)	
		FERNAUD-ESPINOZA, et al., "Differential Activation of Microglia and Astrocytes in Aniso- and Isomorphic Gliotic Tissue," Glia 8 : 277 - 291, 1993	
		FERRARI, et al., "Epidermal Growth Factor Exerts Neuronotrophic Effects on Dopaminergic and GABAergic CNS Neurons: Comparison With Basic Fibroblast Growth Factor," J. Neurosci, Res. 30:493-497, 1991	
		FERRI, et al., "Regulation of regional differences in the differentiation of cerebral cortical neurons by EGF family-matrix interactions," Development 121 : 1151 - 1160, 1995	
		FREED, et al., "Eight Years Experience with Fetal Neurotransplantation in Patients with Advanced Parkinsons Disease," Soc. Neurosci. Abstr. 22 : 481 - 3, 1996	
		FREY, II et al., "Delivery of 125I-NGF to the Brain via the Olfactory Route," Drug Delivery 4:87-92, 1997	
		FRIGULS, et al., "Activation of ERK and Akt signaling in focal cerebral ischemia: modulation by TGF- $\alpha$ and involvement of NMDA Receptor", Neurobiology of Disease 11, 443-456 (2002)	
		FUXE, et al., "Trophic Regulation of the Basal Ganglia: Focus on Dopamine Neurons", Journal of Chemical Neuroanatomy 9 (1995) 79-80, Elsevier Science Ltd., Oxford UK, 1994, 618 pp., ISBN 0-08-042276-4	
		GILL, "Regulation of EGF Receptor Expression and Function" (1990) Molecular Reproduction and Development 27:46-53*	
		GLEASON, et al., "Ependymal stem cells divide asymmetrically and transfer progeny into the subventricular zone when activated by injury", Neuroscience, vol. 156, Issue 1, September 22, 2008, pp. 81-88	
Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/739,933
				Filing Date	December 18, 2000; Conf. No. 4882
				First Named Inventor	James Steven Reid
				Art Unit	1649
				Examiner Name	STACEY NEE MACFARLANE
Sheet	5	of	12	Attorney Docket Number	108091-0002-103

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		GOMEZ-PINILLA, et al., "Epidermal growth factor receptor immunoreactivity in rat brain. Development and cellular locations," Brain Res. 438:385-390, 1988	
		GOULD E., et al., "Neurogenesis in the Neocortex of Adult Primates," (Science 286:548-552 – 1999) p. 3, 13	
		GREENGARD, et al., "Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade," Neuron 23:435-447 — (1999)	
		GROTENDORST, et al., "EGF and TGF-alpha Are Potent Chemoattractants for Endothelial Cells and EGF-like Peptides are Present at Sites of Tissue Regeneration," J. Cell. Physiol. 1989. 139:617-623	
		GUERRA-CRESPO, et al., "Intranasal administration of PEGylated transforming growth factor-alpha improves behavioral deficits in a chronic stroke model." J. Stroke Cerebrovasc Dis. Jan 2010;19(1):3-9*	
		HADJICONSTANTINO, et al., "Epidermal Growth Factor Enhances Striatal Dopaminergic Parameters in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Mouse," J. Neurochem. 57:479-482, 1991	
		HEFTI F., "Neurotrophic Factor Therapy for Nervous System Degenerative Diseases," J. Neurobiol. 25:1418-1435, 1994	
		HISHIKI, et al., "Glial Cell Line-derived Neurotrophic Factor/Neurturin-induced Differentiation and Its Enhancement by Retinoic Acid in Primary Human Neuroblastomas Express c-Ret, GFRα-1, and GFRα-2," Cancer Res. 58 : 2158 – 2165	
		JACKOWSKI et al, "Neural injury repair: hope for the future as barriers to effective CNS regeneration become clearer", Br. J. of Neurosurg., 9:303-317, 1995*	
		JIN K., "Neurogenesis in dentate subgranular zone and rostral subventricular zone after focal cerebral ischemia in the rat," Proc Natl Acad Sci U S A 98:4710-4714 – (2001)	
		JU, et al., "TGFα Enhances Locomotion of Cultured Human Keratinocytes," J. Invest. Dermatol. 100 : 628-632, 1993	
		JUNIER, et al., "Transforming Growth Factor α (TGFα) Expression in Degenerating Motoneurons of the Murine Mutant Wobbler: A Neuronal Signal for Astroglia?", J. Neurosci. 14 : 4206 – 4216, 1994	
		JUNIER M-P., "What role(s) for TGFα in the central nervous system?," Prog. Neurobiol. 2000. 62:443-473	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/739,933
				Filing Date	December 18, 2000; Conf. No. 4882
				First Named Inventor	James Steven Reid
				Art Unit	1649
				Examiner Name	STACEY NEE MACFARLANE
Sheet	6	of	12	Attorney Docket Number	108091-0002-103

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		KESAVAN, et al., "Regulation of stability and synthesis of EGF-receptor MRNAs encoding for intact and truncated receptor forms," <i>Oncogene</i> 5 : 483 - 488, 1990	
		KIREEVA, et al., "Cyr61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion," <i>Mol. Cell. Biol.</i> , 16:1326, 1996	
		KIRSCHENBAUM, et al., " <i>In vitro</i> Neuronal Production and Differentiation by Precursor Cells Derived from the Adult Human Forebrain," <i>Cerebral Cortex</i> 4 : 576 - 589, 1994	
		KNUSEL, et al., "Selective and Nonselective Stimulation of Central Cholinergic and Dopaminergic Development <i>in vitro</i> by Nerve Growth Factor, Basic Fibroblast Growth Factor, Epidermal Growth Factor, Insulin and the Insulin-like Growth Factors I and II," and nonJ. <i>Neurosci.</i> 10:558-570, 1990	
		KRUSHEL, et al., "Neural cell adhesion molecule (N-CAM) inhibits astrocyte proliferation after injury to different regions of the adult rat brain," <i>Proc. Natl. Acad. Sci. USA</i> 92 : 4323 - 4327, 1995	
		KUDLOW, et al., "Transforming Growth Factor- $\alpha$ in the Mammalian Brain," <i>J. Biol. Chem.</i> 264:3880-3883, 1989	
		LACHYANKAR, et al., "CNS Precursor Cells That Express TRK Receptors: Induction of Different Cell Fates by Neurotrophins," <i>Soc. Neurosci. Abstr.</i> 22 : 394.7, 1996	
		LAZAR, et al., "Regional Distribution and Developmental Expression of Epidermal Growth Factor and Transforming Growth Factor- $\alpha$ mRNA in Mouse Brain by a Quantitative Nuclease Protection Assay," <i>J. Neurosci.</i> 12:1688-1697, 1992	
		LEE et al., "Developmental expression of rat transforming growth factor- $\alpha$ mRNA", <i>Mol. Cell. Biol.</i> 5:3655-3646, 1985	
		LEE, et al., "Transforming growth factor $\alpha$ : expression, regulation, and biological activities," <i>Pharmacol Rev</i> 47:51-85 - (1995)	
		LEKER, et al., "Transforming growth factor $\alpha$ induces angiogenesis and neurogenesis following stroke", <i>Neuroscience</i> 163 (2009) 233-243	
		LEND AHL, et al., "CNS Stem Cells Express a New Class of Intermediate Filament Protein," <i>Cell</i> 60 : 585-595, 1990	
		LEVINE, et al., "Sonic Hedgehog Promotes Rod Photoreceptor Differentiation in Mammalian Retinal Cells <i>In Vitro</i> ," <i>J. Neurosci.</i> : 6277 - 6288, 1997	
		LIN, et al., "Expression of CD34 in endothelial cells, hematopoietic progenitors and nervous cells in fetal and adult mouse tissues," <i>Eur. J. Immunol.</i> 1995. 25:1508-1516	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	09/739,933
				Filing Date	December 18, 2000; Conf. No. 4882
				First Named Inventor	James Steven Reid
				Art Unit	1649
				Examiner Name	STACEY NEE MACFARLANE
Sheet	7	of	12	Attorney Docket Number	108091-0002-103

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		LINDVALL, et al., "Stem cells for the treatment of neurological disorders," Nature 441:1094-1096 - (2006) p. 14	
		LINDEMANN, et al., "Expression of NCAM mRNA and Polypeptides in Aging Rat Brain," Int. J. Devel. Neurosci. 11 : 71 - 81, 1993	
		LOIS, et al., "Proliferating subventricular zone cells in the adult mammalian forebrain can differentiate into neurons and glia," Proc. Natl. Acad. Sci. USA 90:2074-2077, 1993	
		LOIS, et al., "Chain Migration of Neuronal Precursors," Science 271 : 978 - 981, 1996	
		LOKESHWAR, et al., "Protamine Enhances Epidermal Growth Factor (EGF)-stimulated Mitogenesis by Increasing Cell Surface EGF Receptor Number," J. Biol. Chem. 264:19318 - 19326, 1989	
		LOUGHLIN, et al., "Mesostriatal Projections from Ventral Tegmentum and Dorsal Raphe: Cells Project Ipsilaterally or Contralaterally But Not Bilaterally," Neurosci. Lett. 32 : 11 - 16, 1982	
		LOUGHLIN, et al., "Postnatal Ontogeny Of Transforming Growth Factor, Alpha And Epidermal Growth Factor mRNA In Rat Brain", Dept. Anst. And Neurobio., Univ Calif., Irvine, Irvine, CA 92717, Society for Neuroscience Abstracts Volume 20, 1994, p. 40	
		LUNDBERG, et al., "Conditionally Immortalized Neural Progenitor Cells Grafted to the Striatum Exhibit Site-Specific Neuronal Differentiation and Establish Connections with the Host Globus Pallidus", Neurobiology of Disease, 3(1):33-50, February 1996	
		LUSKIN, M., "Restricted Proliferation and Migration of Postnatally Generated Neurons Derived from the Forebrain Subventricular Zone," Neuron 11 :173 -189, 1993	
		MA, et al., "Intranasal delivery of transforming growth factor-beta1 in mice after stroke reduces infarct volume and increases neurogenesis in the subventricular zone," BMC Neurosci 9:117 - (2008)	
		MARTINEZ-MORALES et al., "Vitronectin is expressed in the ventral region of the neural tube and promotes the differentiation of motor neurons," Development 124 : 5139 - 5147	
		MCINNES, et al., "Growth Factor Receptors: Structure, Mechanism, and Drug Discovery" (1998) Protein Engineering Network of Centres of Excellence, Univ. of Alberta, Canada*	
		MEZEY, et al., "Turning Blood into Brain: Cells Bearing Neuronal Antigens Generated in Vivo from Bone Marrow," (2000) Science 290:1779	
		MOGI, et al., "Interleukin-1B, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients," Neurosci. Lett. 180 : 147 - 150, 1994	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	09/739,933
				Filing Date	December 18, 2000; Conf. No. 4882
				First Named Inventor	James Steven Reid
				Art Unit	1649
				Examiner Name	STACEY NEE MACFARLANE
Sheet	8	of	12	Attorney Docket Number	108091-0002-103

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		MORRISON, et al., "Trophic Stimulation of Cultured Neurons from Neonatal Rat Brain by Epidermal Growth Factor," Science 238:72-75, 1987	
		MORSHEAD, et al., "Postmitotic Death Is the Fate of Constitutively Proliferating Cells in the Subependymal Layer of the Adult Mouse Brain," J. Neurosci. 249-256, 1992	
		MORSHEAD, et al., "Neural Stem Cells in the Adult Mammalian Forebrain: A Relatively Quiescent Subpopulation of Subependymal Cells," Neuron 13 : 1071 - 1082, 1994	
		NAKATOMI, et al., "Regeneration of Hippocampal Pyramidal Neurons after Ischemic Brain Injury by Recruitment of Endogeneous Neural Progenitors," Cell, 110:429-441 August 23, 2002	
		"New stroke therapy successful in rats: protein completely restores motor function", <a href="http://www.sciencedaily.com/releases/2010/01/100112135034.htm">http://www.sciencedaily.com/releases/2010/01/100112135034.htm</a> , 1/12/10	
		NeuroRepair Validates IP with Lab's Success in New Stroke Therapy, <a href="http://www.nrweb.com/releases/neuroregenerative/theranv/nrweb3583304.htm">http://www.nrweb.com/releases/neuroregenerative/theranv/nrweb3583304.htm</a>	
		NIETO-SAMPEDRO, et al., "Epidermal growth factor receptor immunoreactivity in rat brain astrocytes. Response to injury," Neurosci. Lett. 91 : 276 - 282, 1988	
		NIHEI, et al., "Newoflament and Neural Cell Adhesion Mo1ecul.e Immunocytochemistry of Huntington's Disease Striatum," Ann. Neurol. 31 : 59 - 63, 1992	
		PAGANI, et al., "Tissue-specific Splicing Pattern of Fibronectin Messenger RNA Precursor during Development and Aging in Rat," J. Cell Biol. 113 : 1223 - 1229, 1991	
		PAN, et al., "TGF $\alpha$ and the Blood-Brain Barrier: Accumulation in Cerebral Vasculature", Exp. Neurol. 1999. 160:454-459*	
		PANAGAKOS F., "Transforming Growth Factor - Alpha Stimulates Chemotaxis of Osteoblasts and Osteoblast-like Cells <i>In Vitro</i> ," Biochem. Mol. Biol. Int. 33 : 643 - 650, 1994	
		PARDRIDGE WM, "Drug Targeting to the Brain," Pharm Res 24:1733:1744 (2007)	
		PARK, et al., "Protection from 1-methyl-4-phenylpyridinium (MPP+) toxicity and stimulation of regrowth of MPP+-damaged dopaminergic fibers by treatment of mesencephalic cultures with EGF and basic FGF," Brain Res. 599:83-97, 1992	
		PAWSON et al. "Assembly of Cell Regulatory Systems Through Protein Interaction Domains", 2003, Science 300:445-452*	
		PESHEVA, et al., "Expression and localization of the Fibronectin Receptor in the Mouse nervous System," J. Neurosci. Res. 20 : 420 - 430, 1988	

Examiner Signature	Date Considered
-----------------------	--------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/739,933
				Filing Date	December 18, 2000; Conf. No. 4882
				First Named Inventor	James Steven Reid
				Art Unit	1649
				Examiner Name	STACEY NEE MACFARLANE
Sheet	9	of	12	Attorney Docket Number	108091-0002-103

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		POLTORAK, et al., "Effects of Frontal Cortical Lesions on Mouse Striatum: Reorganization of Cell Recognition Molecule, Glial Fiber, and Synaptic Protein Expression in the Dorsomedial Striatum," J. Neurosci. 13 : 2217 - 2229, 1993	
		POPA-WAGNER, et al., "Decortication and striatal mRNA: Increases of mRNA for fibronectin, but not of NCAM or $\alpha$ -1 tubulin," Neuroreport 3 : 853 - 856, 1992	
		PRIETO, et al., "Localization during Development of Alternatively Spliced forms of Cytotactin mRNA by In Situ Hybridization," J. Cell Biol. 111 : 685 - 698, 1990	
		QUIRION, et al., "Visualization of Growth Factor Receptor Sites in Rat Forebrain," Synapse 2:212-218, 1988	
		RAHMAN M - Neurosurg Focus 27:E12 - Early history of the stereotactic apparatus in neurosurgery - (2009)	
		RAKIC P "Limits of Neurogenesis in Primates", Science 227:1054-1056 (1985)	
		RAY et al., "Characterization Of Neural Progenitor Cells Isolated And Cultured From Different Regions Of Adult Rat Spinal Cord," Soc. Neurosci. Abstr. 22 : 394 - 5 1996	
		RAYMOND et al., " Characterization of Epidermal Growth Factor Receptor Induction by Retinoic Acid in a Chemically Transformed Rat Liver Cell Line", Cell. Growth Diff. 1 : 393 - 399	
		REID et al, Abstracts, Society of Neuroscience Abstracts, Vol. 22 Part 3, 26th Annual Meeting, Washington, D.C. November 16-21, 1996	
		RENEKER et al., "TGF $\alpha$ can act as a chemoattractant to perioptic mesenchymal cells in developing mouse eyes," Development 121 : 1669 - 1680, 1995	
		REYNOLDS, "Generation of Neurons and Astrocytes from Isolated Cells of the Adult Mammalian Central Nervous System," (1992) Science 255:1707-1710, 1992	
		REYNOLDS et al., "A Multipotent EGF-Responsive Striatal Embryonic Progenitor Cell Produces Neurons and Astrocytes," J. Neurosci. 12 : 4565 - 4574	
		ROUSSELOT, et al., "Embryonic (PSA) N-CAM reveals chains of migrating neuroblasts between the lateral ventricle and the olfactory bulb of adult mice", The Journal of Comparative Neurology, 351(1):51 - 61, 1995	
		SAKANE T, Pardridge WM, "Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity," Pharm Res 14:1085-1091 (1997)	
		SANCHEZ RAMOS, "Adult Bone Marrow Stromal Cells Differentiate into Neural Cells in Vitro," (2000) Experimental Neurology 164:247	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/739,933
				Filing Date	December 18, 2000; Conf. No. 4882
				First Named Inventor	James Steven Reid
				Art Unit	1649
				Examiner Name	STACEY NEE MACFARLANE
Sheet	10	of	12	Attorney Docket Number	108091-0002-103

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		SCHNEIDER et al., "Enhanced restoration of striatal dopamine concentrations by combined OM! ganglioside and neurotrophic factor treatments," Brain Res. 674:260-264, 1995	
		SEROOGY et al., "Proliferative zones of postnatal rat brain express epidermal growth factor receptor mRNA," Brain Res. 670:157-164, 1995	
		SEROOGY et al., "Cellular Localization of Transforming Growth Factor- $\alpha$ mRNA in Rat Forebrain," J. Neurochem. 60 : 1777 - 1782, 1993	
		SEROOGY et al., "Expression of EGF receptor mRNA in rat nigrostriatal system", Neuroreport 6:105-108, 1994	
		SNYDER et al., "Neuronal Regeneration, Reorganization, and Repair," (1997) Adv. Neurol. 72:121-132	
		SNYDER et al., "Multipotent neural precursors can differentiate toward replacement of neurons undergoing targeted apoptotic degeneration in adult mouse neocortex," (1997) Proc. Natl. Acad. Sci. USA 94:11663-11668	
		SZELE et al., "Cortical Lesions Induce an Increase in Cell Number and PSA-NCAM Expression in the Subventricular Zone of Adult Rats," J. Comp Neurol. 368 : 439 - 454, 1996	
		SZELE et al., "Pattern Of Expression Of Highly Pol Ysial Yla Ted Neural Cell Adhesion Molecule In The Developing And Adult Rat Stria Tum," Neurosci. 60 : 133 - 144, 1994	
		T HART et al. "The use of animal models to investigate the pathogenesis of neuroinflammatory disorders of the central nervous system", Curr. Opin. Neurol. 2003. 16:375-383*	
		TANABE et al., "Induction of motor neurons by Sonic hedgehog is independent of floor plate differentiation Yasuto Tanabe, Henk Roelink and Thomas M. Jessell," Curr. Biol. 5 : 651 - 658, 1995	
		THOMPSON et al., "Regulation of Epidermal Growth Factor Receptor Gene Expression by Retinoic Acid and Epidermal Growth Factor," J. Biol. Chem. 264 : 3230 - 3234, 1989	
		TOMA et al., "Spatiotemporal Increases in Epidermal Growth Factor Receptors following Peripheral Nerve Injury," J. Neurosci. 12 : 2504 - 2515, 1992	
		VICARIO-ABEJON et al., "Cerebellar Precursors Transplanted to the Neonatal Dentate Gyrus Express Features Characteristic of Hippocampal Neurons," Neuron 15 : 105 - 114, 1995	
		VICARIO-ABEJON et al., "Autoradiographic study of [125I] Epidermal growth factor-binding sites in the mesencephalon of control and parkinsonian brains post-mortem," J. Neurosci. 15 : 6351 - 6363, 1995	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/739,933
				Filing Date	December 18, 2000; Conf. No. 4882
				First Named Inventor	James Steven Reid
				Art Unit	1649
				Examiner Name	STACEY NEE MACFARLANE
Sheet	11	of	12	Attorney Docket Number	108091-0002-103

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		VILLARES et al., "Autoradiographic study of [12I I]epidermal growth factor-binding sites in the mesencephalon of control and parkinsonian brains post-mortem," Brain Res. 628 : 72 - 76, 1993	
		WERNER et al., "Localization of Immunoreactive Epidermal Growth Factor Receptors in Human Nervous System," J. Histochem, Cytochem. 36:81-86, 1988	
		WOODBURY, "Adult Rat and Human Bone Marrow Stromal Cells Differentiate Into Neurons," (2000) J. Neuroscience Research 61:364	
		WYSS - CORAY et al., "Increased Central Nervous System Production of Extracellular Matrix Components and Development of Hydrocephalus in Transgenic Mice Overexpressing Transforming Growth Factor-J31," Am. J. Pathol. 147 : 53 - 67, 1995	
		XIAN et al., "Roles of Transforming Growth Factor-a and Related Molecules in the Nervous System," Mo. Neurobiol. 1999. 20:157-183	
		YOUNG et al., Neuronal Differentiation and Morphological Integration of Hippocampal Progenitor Cells Transplanted to the Retina of Immature and Mature Dystrophic Rats," (Mol. Cell. Neurosciences 16:197, 2000	
		ZHANG et al., "Transforming growth factor $\alpha$ and a PC12-derived growth factor induce neurites in PC12 cells and enhance the survival of embryonic brain neurons", Cell. Regul. 1:511-521, 1990	
		ZHAO C - Cell 132:645-660 – Mechanisms and functional implications of adult neurogenesis – (2008)	
		ZURN e t al., "Combined Effects of GDNF, BDNF, and CNTF on Motoneuron Differentiation In Vitro," J. Neurosci. Res. 44 : 133 - 141, 1996	
		NEUROREPAIR, INC. v. THE NATH LAW GROUP –EXPERT REPORT OF RICHARD WARBURG, April 8, 2010	
		NEUROREPAIR, INC. v. THE NATH LAW GROUP – EXPERT REPORT OF JAMES FALLON, April 8, 2010	
		NEUROREPAIR, INC. v. THE NATH LAW GROUP – EXPERT REPORT OF MARC J. TETEL, April 8, 2010	
		NEUROREPAIR, INC. v. THE NATH LAW GROUP – REBUTTAL EXPERT REPORT OF JAMES FALLON, April 22, 2010	
		NEUROREPAIR, INC. v. THE NATH LAW GROUP – SUPPLEMENTAL EXPERT REPORT OF MARC J. TETEL, October 25, 2010	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.